{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:34:49Z","timestamp":1763037289838,"version":"build-2065373602"},"reference-count":55,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ift.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Food Science"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Imatinib, the prototype BCR\u2010ABL tyrosine kinase inhibitor (TKI), is the first\u2010line treatment for Philadelphia chromosome\u2010positive chronic myeloid leukemia (CML) in the chronic phase. However, a subgroup of patients exhibit poor response or experience relapse. This issue may be overcome by combination therapy using natural compounds. Neferine, a major bisbenzylisoquinoline alkaloid extracted from \u201clotus plumule\u201d (seed embryo of lotus) commonly used in traditional Chinese medicine and tea, was used herein in the combination treatment of CML. The MTT assay showed that neferine exerted cytotoxicity in primary CML cells in a dose\u2010dependent manner. Moreover, low concentrations of neferine (4 and 8 \u00b5M) sensitized primary CML cells to imatinib (CI &lt; 1), and significantly decreased its IC\n                      <jats:sub>50<\/jats:sub>\n                      from 0.70 \u00b1 0.10 to 0.32 \u00b1 0.06 \u00b5M and 0.16 \u00b1 0.02 \u00b5M, respectively. Cotreatment of neferine and imatinib significantly decreased the expression of BCR\u2010ABL protein and its molecular chaperone heat shock protein 90 (Hsp90) mRNA and protein levels, and further decreased phospho\u2010extracellular regulated protein kinase 1\/2 (p\u2010Erk1\/2) and myeloid cell leukemia (Mcl\u20101) expression. These results suggest that neferine might be a potential imatinib sensitizer in CML treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Practical application<\/jats:title>\n                    <jats:p>In China, Lotus plumule, the green embryo of lotus, is used as a tea and as a source of herbal medicine in the treatment of anxiety, insomnia, spermatorrhea, and thirst. Additional, neferine, a bisbenzylisoquinoline alkaloid extracted from lotus plumule has been shown to have antitumor potential. Herein, the effect of neferine and imatinib cotreatment on primary CML cells obtained from CML patients was assessed, with a synergistic\u00a0effect being observed between the two compounds. Therefore, neferine might be a promising natural compound to potentiate imatinib in CML patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1750-3841.14484","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T18:50:03Z","timestamp":1552503003000},"page":"904-910","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Neferine in the Lotus\u00a0Plumule Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia Cells\n                    <i>In Vitro<\/i>"],"prefix":"10.1111","volume":"84","author":[{"given":"Yalan","family":"Zhang","sequence":"first","affiliation":[{"name":"Xiangya Hospital Central South Univ.  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhang","family":"Xiao","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South Univ.  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qixing","family":"Dong","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South Univ.  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South Univ.  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9732-7039","authenticated-orcid":false,"given":"Qun","family":"Qin","sequence":"additional","affiliation":[{"name":"Xiangya Hospital Central South Univ.  Changsha China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,3,13]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0749"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201664"},{"issue":"7","key":"e_1_2_8_4_1","first-page":"355","article-title":"The heat shock protein 90 antagonist geldanamycin alters chaperone association with P210BCR\u2010ABL and v\u2010SRC proteins before their degradation by the proteasome","volume":"11","author":"An W. G.","year":"2000","journal-title":"Cell Growth & Differentiation the Molecular Biology Journal of the American Association for Cancer Research"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31963"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-810986"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/jf0607011"},{"issue":"5","key":"e_1_2_8_8_1","first-page":"933","article-title":"Geldanamycin selectively destabilizes and conformationally alters mutated p53","volume":"11","author":"Blagosklonny M. V.","year":"1995","journal-title":"Oncogene"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1309\/VQXFT880JXC7QD2W"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402889"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24591"},{"issue":"686","key":"e_1_2_8_12_1","first-page":"85","article-title":"Genomic amplification of BCR\u2010ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia","volume":"3","author":"Chandran R. K.","year":"2018","journal-title":"Gene"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1142\/S0192415X15500159"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/asheducation-2018.1.161","article-title":"The argument for using imatinib in CML","volume":"1","author":"Claudiani S.","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201400"},{"issue":"2","key":"e_1_2_8_16_1","first-page":"753","article-title":"The significance of Hsp90aa1, Hsp90ab1 and Hsp90b1 gene polymorphisms in a Turkish population with non\u2010small cell lung cancer","volume":"34","author":"Coskunpinar E.","year":"2014","journal-title":"Anticancer Research"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep41616"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207692"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.26006"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.6.1807"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538"},{"issue":"2","key":"e_1_2_8_22_1","first-page":"35","article-title":"Antiarrhythmic efficacy of neferine assessed by programmed electrical stimulation in a canine model of electropharmacology","volume":"11","author":"Guo Z.","year":"2002","journal-title":"Journal of Chinese Pharmaceutical Sciences"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403426"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0408-7"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/jf103382h"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-011-1138-y"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(01)00633-6"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00238"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20181414"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2009.09.006"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2008.05687.x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2015.12.001"},{"key":"e_1_2_8_33_1","doi-asserted-by":"crossref","unstructured":"Marum J. E. Yeung D. T. Purins L. Reynolds J. Parker W. T. Stangl D. \u2026Branford S.(2017).ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure 1(18) 1369\u20131381.","DOI":"10.1182\/bloodadvances.2017006825"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2147"},{"key":"e_1_2_8_35_1","first-page":"273","volume-title":"Pharmacopoeia of People Republic of China. Part 1","author":"National Pharmacopoeia Committee","year":"2015"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.01.005"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23123110"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/biof.1115"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2013.05.138"},{"issue":"12","key":"e_1_2_8_40_1","first-page":"1086","article-title":"Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid derivatives","volume":"23","author":"Qian J. Q.","year":"2002","journal-title":"Acta Pharmacologica Sinica"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.550075"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1258\/ebm.2012.011423"},{"issue":"2","key":"e_1_2_8_43_1","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR\u2010ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai K.","year":"1996","journal-title":"Oncogene"},{"issue":"1","key":"e_1_2_8_44_1","first-page":"143","article-title":"Lotus\u2014A potential nutraceutical source","volume":"3","author":"Sridhar K. R.","year":"2007","journal-title":"Journal of Agricultural Technology"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403241"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10212"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2012.000822"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.4238\/2015.June.11.17"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-018-0097-8"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-4737-8"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2013.03.024"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3442-y"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(92)90008-U"},{"issue":"11","key":"e_1_2_8_54_1","first-page":"2110","article-title":"Advances in the bioactivity of Lotus\u2010seed","volume":"33","author":"Zeng S. H.","year":"2012","journal-title":"Chinese Journal of Tropical Crops"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.12.035"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2013.05.018"}],"container-title":["Journal of Food Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1750-3841.14484","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1750-3841.14484","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1750-3841.14484","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ift.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1750-3841.14484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:10:15Z","timestamp":1762186215000},"score":1,"resource":{"primary":{"URL":"https:\/\/ift.onlinelibrary.wiley.com\/doi\/10.1111\/1750-3841.14484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,13]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1111\/1750-3841.14484"],"URL":"https:\/\/doi.org\/10.1111\/1750-3841.14484","archive":["Portico"],"relation":{},"ISSN":["0022-1147","1750-3841"],"issn-type":[{"type":"print","value":"0022-1147"},{"type":"electronic","value":"1750-3841"}],"subject":[],"published":{"date-parts":[[2019,3,13]]},"assertion":[{"value":"2018-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}